Pathophysiological subtypes of Alzheimer’s disease based on cerebrospinal fluid proteomics
暂无分享,去创建一个
K. Blennow | J. Molinuevo | P. Scheltens | F. Barkhof | P. Visser | M. Tsolaki | S. Lovestone | S. Engelborghs | R. Vandenberghe | F. Verhey | J. Streffer | I. Jansen | L. Bertram | B. Tijms | A. Lleó | H. Zetterberg | Fabian Kilpert | C. Teunissen | J. Gobom | P. Martínez-Lage | L. Reus | I. Bos | S. Vos | J. Popp | V. Dobričić | Shengjun Hong | M. ten Kate | V. Dobricic
[1] I. Lindberg,et al. A comprehensive systematic review of CSF proteins and peptides that define Alzheimer’s disease , 2020, Clinical Proteomics.
[2] The Lancet Haematology,et al. Proliferation and differentiation. , 2019, The Lancet. Haematology.
[3] P. Visser,et al. Cerebrospinal fluid proteomics and biological heterogeneity in Alzheimer’s disease: A literature review , 2019, Critical reviews in clinical laboratory sciences.
[4] A. Levey,et al. Integrated proteomics reveals brain-based cerebrospinal fluid biomarkers in asymptomatic and symptomatic Alzheimer’s disease , 2019, Science Advances.
[5] Bin Zhang,et al. Large-scale proteomic analysis of Alzheimer’s disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and astrocyte activation , 2019, bioRxiv.
[6] R. Dobson,et al. Genome-wide association study of Alzheimer’s disease CSF biomarkers in the EMIF-AD Multimodal Biomarker Discovery dataset , 2019, bioRxiv.
[7] Manoj Kumar,et al. INGE GRUNDKE-IQBAL AWARD FOR ALZHEIMER’S RESEARCH: NEUROTOXIC REACTIVE ASTROCYTES ARE INDUCED BY ACTIVATED MICROGLIA , 2019, Alzheimer's & Dementia.
[8] Antonio Núñez Galindo,et al. Proteomes of Paired Human Cerebrospinal Fluid and Plasma: Relation to Blood-Brain Barrier Permeability in Older Adults. , 2019, Journal of proteome research.
[9] Genetic,et al. Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing , 2019, Nature Genetics.
[10] Nick C Fox,et al. Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing , 2019, Nature Genetics.
[11] Timothy J. Hohman,et al. Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer’s disease risk , 2019, Nature Genetics.
[12] G. Church,et al. REST and Neural Gene Network Dysregulation in iPSC Models of Alzheimer’s Disease , 2019, Cell reports.
[13] Melanie A. Huntley,et al. Changes in the Synaptic Proteome in Tauopathy and Rescue of Tau-Induced Synapse Loss by C1q Antibodies , 2018, Neuron.
[14] Martin Eisenacher,et al. The PRIDE database and related tools and resources in 2019: improving support for quantification data , 2018, Nucleic Acids Res..
[15] W. M. van der Flier,et al. Atrophy subtypes in prodromal Alzheimer’s disease are associated with cognitive decline , 2018, Brain : a journal of neurology.
[16] R. Dobson,et al. The EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort characteristics , 2018, Alzheimer's Research & Therapy.
[17] J. Poirier,et al. Bi-directional Association of Cerebrospinal Fluid Immune Markers with Stage of Alzheimer’s Disease Pathogenesis , 2018, Journal of Alzheimer's disease : JAD.
[18] C. Jack,et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease , 2018, Alzheimer's & Dementia.
[19] W. M. van der Flier,et al. Unbiased Approach to Counteract Upward Drift in Cerebrospinal Fluid Amyloid-β 1-42 Analysis Results. , 2018, Clinical chemistry.
[20] K. Blennow,et al. The nonlinear relationship between cerebrospinal fluid Aβ42 and tau in preclinical Alzheimer’s disease , 2018, PloS one.
[21] Berislav V. Zlokovic,et al. Blood–brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders , 2018, Nature Reviews Neurology.
[22] W. M. van der Flier,et al. Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer’s disease , 2018, Alzheimer's Research & Therapy.
[23] Frederik Barkhof,et al. Cognitive subtypes of probable Alzheimer's disease robustly identified in four cohorts , 2017, Alzheimer's & Dementia.
[24] T. Kanekiyo,et al. Blood-Brain Barrier Dysfunction and the Pathogenesis of Alzheimer’s Disease , 2017, International journal of molecular sciences.
[25] Gary Yellen,et al. Neuronal Stimulation Triggers Neuronal Glycolysis and Not Lactate Uptake. , 2017, Cell metabolism.
[26] K. Blennow,et al. Identification of candidate cerebrospinal fluid biomarkers in parkinsonism using quantitative proteomics. , 2017, Parkinsonism & related disorders.
[27] P. Scheltens,et al. Unbiased estimates of cerebrospinal fluid β-amyloid 1–42 cutoffs in a large memory clinic population , 2017, Alzheimer's Research & Therapy.
[28] L. Mucke,et al. Network abnormalities and interneuron dysfunction in Alzheimer disease , 2016, Nature Reviews Neuroscience.
[29] R. Sperling,et al. Bayesian model reveals latent atrophy factors with dissociable cognitive trajectories in Alzheimer’s disease , 2016, Proceedings of the National Academy of Sciences.
[30] A. Smit,et al. Profiling the human hippocampal proteome at all pathologic stages of Alzheimer's disease , 2016, Alzheimer's & Dementia.
[31] Andrew D. Rouillard,et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update , 2016, Nucleic Acids Res..
[32] Kevin L. Boehme,et al. Assessment of the genetic variance of late-onset Alzheimer's disease , 2016, Neurobiology of Aging.
[33] Frederik Barkhof,et al. Atrophy patterns in early clinical stages across distinct phenotypes of Alzheimer's disease , 2015, Human brain mapping.
[34] Daniel S Spellman,et al. Development and evaluation of a multiplexed mass spectrometry based assay for measuring candidate peptide biomarkers in Alzheimer's Disease Neuroimaging Initiative (ADNI) CSF , 2015, Proteomics. Clinical applications.
[35] P. Scheltens,et al. Early onset APOE E4-negative Alzheimer’s disease patients show faster cognitive decline on non-memory domains , 2015, European Neuropsychopharmacology.
[36] Pierre J. Magistretti,et al. A Cellular Perspective on Brain Energy Metabolism and Functional Imaging , 2015, Neuron.
[37] Jack Euesden,et al. PRSice: Polygenic Risk Score software , 2014, Bioinform..
[38] K. Blennow,et al. SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer’s disease , 2014, Molecular Neurodegeneration.
[39] E. Zanier,et al. Versatility of the complement system in neuroinflammation, neurodegeneration and brain homeostasis , 2014, Front. Cell. Neurosci..
[40] J. Olsen,et al. Off-line high-pH reversed-phase fractionation for in-depth phosphoproteomics. , 2014, Journal of proteome research.
[41] T. Maniatis,et al. An RNA-Sequencing Transcriptome and Splicing Database of Glia, Neurons, and Vascular Cells of the Cerebral Cortex , 2014, The Journal of Neuroscience.
[42] Nick C Fox,et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria , 2014, The Lancet Neurology.
[43] D. Holtzman,et al. Neuronal activity regulates extracellular tau in vivo. , 2014, The Journal of experimental medicine.
[44] Nick C Fox,et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease , 2013, Nature Genetics.
[45] Frederik Barkhof,et al. Different patterns of gray matter atrophy in early- and late-onset Alzheimer’s disease , 2013, Neurobiology of Aging.
[46] Anushya Muruganujan,et al. Large-scale gene function analysis with the PANTHER classification system , 2013, Nature Protocols.
[47] Leslie M. Shaw,et al. Longitudinal change in CSF Tau and Aβ biomarkers for up to 48 months in ADNI , 2013, Acta Neuropathologica.
[48] E. Chen,et al. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool , 2013, BMC Bioinformatics.
[49] Wendy Noble,et al. Physiological release of endogenous tau is stimulated by neuronal activity , 2013, EMBO reports.
[50] M. Freedman,et al. Clinical, imaging, and pathological heterogeneity of the Alzheimer's disease syndrome , 2013, Alzheimer's Research & Therapy.
[51] C. Walsh,et al. Microcephaly Gene Links Trithorax and REST/NRSF to Control Neural Stem Cell Proliferation and Differentiation , 2012, Cell.
[52] B. Zlokovic,et al. Neurovascular dysfunction and faulty amyloid β-peptide clearance in Alzheimer disease. , 2012, Cold Spring Harbor perspectives in medicine.
[53] D. Purpura,et al. REST-dependent epigenetic remodeling promotes the in vivo developmental switch in NMDA receptors , 2012, Nature Neuroscience.
[54] A. Fagan,et al. Upcoming candidate cerebrospinal fluid biomarkers of Alzheimer's disease. , 2012, Biomarkers in medicine.
[55] J. Hort,et al. Evaluation of white matter alterations in Alzheimer's disease and normal pressure hydrocephalus as measured by diffusion weighted MRI , 2012, Alzheimer's & Dementia.
[56] C. Jack,et al. MRI in pathologically-defined hippocampal sparing and limbic predominant atypical variants of Alzheimer's disease , 2012, Alzheimer's & Dementia.
[57] W. Kukull,et al. Accuracy of the Clinical Diagnosis of Alzheimer Disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010 , 2012, Journal of neuropathology and experimental neurology.
[58] R. Veerhuis,et al. Complement in the brain. , 2011, Molecular immunology.
[59] Denise C. Park,et al. Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.
[60] J. Morris,et al. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.
[61] Nick C Fox,et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.
[62] M. Albert,et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.
[63] Jee Hoon Roh,et al. Neuronal activity regulates the regional vulnerability to amyloid-β deposition , 2011, Nature Neuroscience.
[64] L. Mucke,et al. Amyloid-β/Fyn–Induced Synaptic, Network, and Cognitive Impairments Depend on Tau Levels in Multiple Mouse Models of Alzheimer's Disease , 2011, The Journal of Neuroscience.
[65] Howard Y. Chang,et al. Long Noncoding RNA as Modular Scaffold of Histone Modification Complexes , 2010, Science.
[66] J. Trojanowski,et al. Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. , 2010, Archives of neurology.
[67] Renaud Gaujoux,et al. A flexible R package for nonnegative matrix factorization , 2010, BMC Bioinformatics.
[68] K. Blennow,et al. CSF biomarkers predict a more malignant outcome in Alzheimer disease , 2010, Neurology.
[69] Jason H. Moore,et al. Alzheimer's Disease Neuroimaging Initiative biomarkers as quantitative phenotypes: Genetics core aims, progress, and plans , 2010, Alzheimer's & Dementia.
[70] T. Beach,et al. Proteomic analysis of Alzheimer's disease cerebrospinal fluid from neuropathologically diagnosed subjects. , 2009, Current Alzheimer research.
[71] R. Petersen,et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects , 2009, Annals of neurology.
[72] W. M. van der Flier,et al. CSF biomarkers in relationship to cognitive profiles in Alzheimer disease , 2009, Neurology.
[73] A. Blokland,et al. Human apolipoprotein C-I expression in mice impairs learning and memory functions Published, JLR Papers in Press, December 26, 2007. , 2008, Journal of Lipid Research.
[74] P. Scheltens,et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria , 2007, The Lancet Neurology.
[75] M. Esiri,et al. Protein co-expression with axonal injury in multiple sclerosis plaques , 2006, Acta Neuropathologica.
[76] Steven Mennerick,et al. Synaptic Activity Regulates Interstitial Fluid Amyloid-β Levels In Vivo , 2005, Neuron.
[77] Hilkka Soininen,et al. Subgroups of Alzheimer's disease based on cerebrospinal fluid molecular markers , 2005, Annals of neurology.
[78] G. Mandel,et al. The many faces of REST oversee epigenetic programming of neuronal genes , 2005, Current Opinion in Neurobiology.
[79] C. Jack,et al. Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment , 2004, Journal of internal medicine.
[80] J. Poirier,et al. Apolipoprotein C-I Expression in the Brain in Alzheimer's Disease , 2001, Neurobiology of Disease.
[81] N. Shachter. Apolipoproteins C-I and C-III as important modulators of lipoprotein metabolism , 2001, Current opinion in lipidology.
[82] H. Sebastian Seung,et al. Learning the parts of objects by non-negative matrix factorization , 1999, Nature.
[83] E. Tangalos,et al. Mild Cognitive Impairment Clinical Characterization and Outcome , 1999 .
[84] J. Rogers,et al. Aggregation State‐Dependent Activation of the Classical Complement Pathway by the Amyloid β Peptide , 1997, Journal of neurochemistry.
[85] P. Mcgeer,et al. Complement activation by beta-amyloid in Alzheimer disease. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[86] K. Blennow,et al. Clinical Heterogeneity of Probable Alzheimer's Disease , 1992, Journal of geriatric psychiatry and neurology.
[87] S. Eisenberg,et al. Mechanisms of inhibition by apolipoprotein C of apolipoprotein E-dependent cellular metabolism of human triglyceride-rich lipoproteins through the low density lipoprotein receptor pathway. , 1991, The Journal of biological chemistry.
[88] M. Folstein,et al. Clinical diagnosis of Alzheimer's disease , 1984, Neurology.